Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results
(MedPage Today) -- Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results.
While first-line pembrolizumab plus...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Hematology | HNSCC | Skin Cancer | Squamous Cell Carcinoma